Robert J. Motzer, MD:It’s been difficult to define whether the toxicity profile is different in the second-line for patients who have experienced toxicities in the first-line. For the most part, some of the toxicities, like hypertension, I find are less in the second-line because patients are already on antihypertensives from experience with hypertension in the first-line therapy, so they’re already into managing that.
I think that the toxicities are managed better in the second-line because there’s often experience with that toxicity for the same class of drug in the first-line. I haven’t really experienced, or been made aware of particularly, the cumulative toxicity, where toxicities seemed to be worse in the second-line because patients experience them in the first-line.
I think the most important thing is recognition of the toxicity and management. So, for all of these different compounds, it’s very important to have interaction between the doctor’s officeparticularly the nurse with the patient—and communication back and forth about the specific toxicities, and have the nurses familiar with the best remedy for the adverse event.
With regard to response rate, generally patients who don’t achieve a favorable response to first-line therapy, have a briefer period of response to the second-line therapy, and it seems to happen across the board, regardless of whatever treatment program we use in second-line.
If a patient is very resistant to sunitinib in first-line, they may benefit from lenvatinib/everolimus second- or third-line, but the response is briefer than patients who achieved long-term response to sunitinib in the first-line. More aggressive tumors in first-line also translate to more aggressive tumors in second-line.
Transcript edited for clarity.
A Japanese-American Male With Recurrent RCC
November 2015
September 2017
July 2018
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Comparing Long-Term Data for IO/IO and IO/TKI in Favorable-Risk mRCC
July 8th 2024During a Case-Based Roundtable® event, Rana McKay, MD, discussed the updated favorable-risk group data for 4 frontline combination trials in renal cell carcinoma in the first article of a 2-part series.
Read More